期刊文献+

舒尼替尼的合成工艺研究 被引量:2

Synthesis of Sunitinib
下载PDF
导出
摘要 以乙酰乙酸乙酯为原料,经Knorr反应、选择性水解、脱羧、甲酰化、水解及缩合得标题化合物。6步总收率为31.1%,各步中间体及目标物结构经MS和1HNMR确证。改进后的方法缩短了步骤、简化了操作、降低了成本,适合于放大制备。 To synthesize Sunitinib as antitumor agent.Target compound was synthesized by using ethyl acetoacetate as starting material via Knorr reaction,selective hydrolysis,decarboxylation,formylation,hydrolysis and condensation.The total yield of the six steps was 31.1% and the structures of the intermediates and the target compound were confirmed by MS and 1HNMR analysis.This improved method is of many advantages,such as simple steps,easy operation,low cost,which can be feasible to large-scale preparation.
出处 《化学试剂》 CAS CSCD 北大核心 2010年第1期82-84,共3页 Chemical Reagents
关键词 舒尼替尼 抗肿瘤药 合成 Sunitinib antitumor agent synthesis
  • 相关文献

参考文献9

  • 1SANDRINE F,CATHERINE D,KARINA V,et al.Safety,pharmacokinetic,and antitumor activity of SU11248,a novel oral multitarget tyrosine kinase inhibior,in patients with cancer[J].J.Clin.Oncol.,2006,24(1):25-35.
  • 2ROBERT R J.Sunitinib:a VERF and PDGF receptor protein kinase and angiogenesis inhibitor[J].Biochem.Biophys.Res.Commun.,2007,356:323-328.
  • 3方正,韦萍,杨照.舒尼替尼合成路线图解[J].中国医药工业杂志,2007,38(11):822-824. 被引量:3
  • 4LI Sun,CHRIS L,SHERI S,et al.Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid(2-diethylaminoethyl)amide,a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase[J].J.Med.Chem.,2003,46(7):1 116-1 119.
  • 5JERAD M M,MONICA J K,BRIAN G C,et al.Early amidation approach to 3-[(4-amido)pyrrol-2-yl]-2-indolinones[J].J.Org.Chem.,2003,68(16):6 447-6 450.
  • 6TANG Peng-chong,MILLER T,LI Xiao-yuan,et al.Pyrrole substituted 2-indolinone protein kinase inhibitors:WO,0 160 814[P].2001-02-15.
  • 7JOHN V B,ROBERT N H.The synthesis of Knorr′s pyrrole by inverse addition[J].Org.Prep.Proced.Int.,1983,15(4):292-295.
  • 8GEOFFREY A C.2-Halopyrroles,synthesis and chemistry[J].J.Org.Chem.,1975,40(22):3 161-3 169.
  • 9SCHNETTLER R A,DAGE R C,GRISAR J M.Pyrrole-3-carboxylate cardiotonic agents:US,4 560 700[P].1985-12-24.

二级参考文献17

  • 1Patyna S, Laird AD, Mendel DB, et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity [J]. Mol Cancer Ther, 2006, 5(7) : 1774-1782.
  • 2Izzedine H, Buhaescul I, Rixe O, et al. Sunitinib malate [J]. Cancer Chemother Pharmacol, 2007, 60 (3): 357-364.
  • 3Marfat A, Carta ME Oxidation of indoles with pyridinium bromide perbromide. A simple and efficient sYnthesis of 7-azaoxindoles [J]. Tetrahedron Lett, 1987, 28 (35) : 4027-4030.
  • 4Kadin SB. 1,3-Disubstituted 2-oxindoles as analgesic and antiinflammatory agents: US, 4721712 [P]. 1988-01-26. (CA 1988, 109: 210892)
  • 5William B, Kenneth HC. Cyclic hydroxamic acids derived from indole [J]. JAm Chem Soc, 1956, 78(1): 221-224.
  • 6Kikukawa Y. New process for producing fluorinated aromatic compound: JP, 6135856 [P]. 1994-05-17.
  • 7Tang PC, Miller T, Li X, et al. Pyrrole substituted 2-indolinone protein kinase inhibitors: WO, 2001060814 [P]. 2001-08-23. (CA2001, 135: 195497)
  • 8Harada K, Nishino S, Hirotsu K, et al. Process for producing 5-fluorooxyindole and for producing intermediates therefor: WO, 2002006228 [P]. 2002-01-24. (CA 2002, 136: 102284)
  • 9Quallich GJ. A general oxindole synthesis [J]. Synthesis, 1993, (7): 51-53.
  • 10Robin DC, Joseph MM, Lawrence EF, et al. Preparation of indoles and oxindoles from N- (tert-butoxycarbonyl) -2- alkylanilines [J]. Synthesis, 1991, (10):871-877.

共引文献2

同被引文献20

  • 1闵真立,姜凤超,张奇.3-取代吲哚酮类化合物的合成及抗肿瘤活性[J].中国药物化学杂志,2005,15(3):129-132. 被引量:10
  • 2谭凤姣,袁春桃,成奋民.课程建设中的行动研究——多步骤有机合成实验教改探讨[J].实验技术与管理,2005,22(7):80-82. 被引量:2
  • 3张陈,陆涛.2-取代-4(3H)-喹唑啉酮类化合物合成研究进展[J].精细化工中间体,2006,36(5):12-15. 被引量:5
  • 4MOTZER R J, MICHAELSON M D, REDMAN B G, et al. Activ- ity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor recep- tor,in patients with metastatic renal cell carcinoma[J]. J Clin On- col,2006,24(1) :16-24.
  • 5FAIVER S, DEMETRI G, SARGENT W, et al. Molecular basis for sunitinib efficacy and future clinical development[J]. Nat Rev Drug Discov, 2007,6 (9) : 734-745.
  • 6ROBERTS L R. Sorafenib in liver cancer--just the beginning[J]. N Engl J Meal,2008,359(4) ,420-422.
  • 7WELSTEAD W J,MORAN H W,STAUFFER H F,et al. Anti- inflammatory agents. 1. Synthesis and antiinflammatory activity of 2-amino-3-benzoylphenylacetic acid[J]. J Med Chem, 1979,22 (9): 1074-1079.
  • 8CHRISTIAN R, EMILE B. Ethyl (4-N-acylaminopyridin-3-yl) glyoxylate and 5-azaisatin as new synthons for a route to various new polyheterocycles[J]. Heterocycl Chem, 1997,34 (2) : 441- 444.
  • 9GASSMAN P G,CUE J. A general method for the synthesis of i- satins[J]. J Org Chem, 1977, (42): 1344-1348.
  • 10RICE K C, BOONE B J,RUBIN A B. Synthesis, antimalarial ac- tivity, and phototoxicity of some benzo(h) quinoline-4-methanols[J]. J Med Chem, 1976,19(7) ,887-892.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部